Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
2017/03/01 by Sang Joon Park, Jae Young Jang, Soung Won Jeong +10 · 25 citations
Medicine · #Hepatocellular Carcinoma Treatment and Prognosis #Pancreatic and Hepatic Oncology Research #Ovarian cancer diagnosis and treatment
paper · doi:10.1097/md.0000000000005811
Abstract
Alpha-fetoprotein (AFP), Lens culinaris-agglutinin-reactive fraction of AFP (AFP-L3), and protein induced by vitamin K absence or antagonist-II (PIVKA-II) are widely used as tumor markers for the diagnosis of hepatocellular carcinoma (HCC). This study compared the diagnostic values of AFP, AFP-L3, and PIVKA-II individually and in combination to find the best biomarker or biomarker panel.Seventy-nine patients with newly diagnosed HCC and 77 non-HCC control patients with liver cirrhosis were enrolled. AFP, AFP-L3, and PIVKA-II were measured in the same serum samples using microchip capillary electrophoresis and a liquid-phase binding assay on an automatic analyzer. Receiver-operating characteristic curve analyses were also applied to all combinations of the markers.When the 3 biomarkers were analyzed individually, AFP showed the largest area under the receiver-operating characteristic curve (AUC) (0.751). For combinations of the biomarkers, the AUC was highest (0.765) for "PIVKA-II > 40 mAU/mL and AFP > 10 ng/mL." The combination of "PIVKA-II > 40 mAU/mL and AFP > 10 ng/mL and AFP-L3 > 10%" had worse sensitivity and lower AUC (P = 0.001). The highest AUC of a single biomarker was highest for AFP and of a combination was "PIVKA-II > 40 mAU/mL and AFP > 10 ng/mL," with this also being the case when the cut-off value of AFP and AFP-L3 was changed.Alpha-fetoprotein showed the best diagnostic performance as a single biomarker for HCC. The diagnostic value of AFP was improved by combining it with PIVKA-II, but adding AFP-L3 did not contribute to the ability to distinguish between HCC and non-HCC liver cirrhosis. These findings were not altered when the cut-off value of AFP and AFP-L3 was changed.
Cited by
- MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. [europepmc]
- Serum microRNA-125a-5p as a potential biomarker of HCV-associated hepatocellular carcinoma. [europepmc]
- Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. [europepmc]
- Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal? [europepmc]
- Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. [europepmc]
- The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. [europepmc]
- Novel biomarkers for the management of chronic hepatitis B. [europepmc]
- Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. [europepmc]
- High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis. [europepmc]
- Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. [europepmc]
- Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma. [europepmc]
- Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine. [europepmc]
- The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. [europepmc]
- Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. [europepmc]
- Plasma circRNAs as Biomarkers in Cancer. [europepmc]
- Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer. [europepmc]
- Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma. [europepmc]
- Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level. [europepmc]
- Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. [europepmc]
- A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. [europepmc]
- Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy. [europepmc]
- A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma. [europepmc]
- Diagnostic Significance of hsa-miR-21-5p, hsa-miR-192-5p, hsa-miR-155-5p, hsa-miR-199a-5p Panel and Ratios in Hepatocellular Carcinoma on Top of Liver Cirrhosis in HCV-Infected Patients. [europepmc]
- Application and progress of the detection technologies in hepatocellular carcinoma. [europepmc]
- Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis. [europepmc]
Related